Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 100

Sort by

Sort Order Select

Meeting Abstracts

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, CASPER K. NIELSEN, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):801-P

https://doi.org/10.2337/db23-801-P

Published: 20 June 2023

View article titled, 801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

Meeting Abstracts

233-OR: The Beta-Cell Specific Deletion of Complement 1q-Like-3 Secreted Protein Improves Beta-Cell Function and Glucose Homeostasis

MD MOSTAFIZUR RAHMAN, HAIFA ALSHARIF, AVA MICHL, SUSHANT BHATNAGAR

Diabetes 2023;72(Supplement_1):233-OR

https://doi.org/10.2337/db23-233-OR

Published: 20 June 2023

View article titled, 233-OR: The Beta-Cell Specific Deletion of Complement 1q-Like-3 Secreted Protein Improves Beta-Cell Function and Glucose Homeostasis

Meeting Abstracts

14-OR: Harmine and Exenatide Combination Increases Human ß-Cell Survival

CAROLINA ROSSELOT, YANSUI LI, DANIELA GUEVARA, KARA A. BELIARD, RANDY KANG, PENG WANG, KEYA THAKKAR, GEMING LU, ROBERT J. DEVITA, ANDREW F. STEWART, ADOLFO GARCIA-OCANA

Diabetes 2022;71(Supplement_1):14-OR

https://doi.org/10.2337/db22-14-OR

Published: 01 June 2022

View article titled, 14-OR: Harmine and Exenatide Combination Increases Human ß-Cell Survival

Meeting Abstracts

895-P: External Validation of the BRAVO Diabetes Model Using Data from the EXSCEL Study

YIXUE SHAO, SHU NIU, LIZHENG SHI, VIVIAN FONSECA, HUI SHAO

Diabetes 2022;71(Supplement_1):895-P

https://doi.org/10.2337/db22-895-P

Published: 01 June 2022

View article titled, 895-P: External Validation of the BRAVO Diabetes Model Using Data from the EXSCEL Study

Meeting Abstracts

10-OR: Combination Therapy with Anti-CD3 Antibody and Harmine plus Exendin-4 Enhances Remission from Recent-Onset Type 1 Diabetes.

GEMING LU, RANDY KANG, YANSUI LI, PENG WANG, CAROLINA ROSSELOT, ROBERT J. DEVITA, ANDREW F. STEWART, ADOLFO GARCIA-OCANA

Diabetes 2022;71(Supplement_1):10-OR

https://doi.org/10.2337/db22-10-OR

Published: 01 June 2022

View article titled, 10-OR: Combination Therapy with Anti-CD3 Antibody and Harmine plus Exendin-4 Enhances Remission from Recent-Onset Type 1 Diabetes.

Meeting Abstracts

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, TINA VILSBØLL, HENRIK U. ANDERSEN, FILIP K. KNOP

Diabetes 2022;71(Supplement_1):745-P

https://doi.org/10.2337/db22-745-P

Published: 01 June 2022

View article titled, 745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

Meeting Abstracts

229-LB: Quantification of GLP-1R Internalization and Recycling in Live ß Cells

SARAH M. GRAY, KYLE SLOOP, PETER RAVN, JONATHAN CAMPBELL, DAVID A. D’ALESSIO

Diabetes 2021;70(Supplement_1):229-LB

https://doi.org/10.2337/db21-229-LB

Published: 01 June 2021

View article titled, 229-LB: Quantification of GLP-1R Internalization and Recycling in Live ß Cells

Meeting Abstracts

641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide

JIN G. JUNG

Diabetes 2021;70(Supplement_1):641-P

https://doi.org/10.2337/db21-641-P

Published: 01 June 2021

View article titled, 641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide

Meeting Abstracts

91-LB: Once-Weekly Exenatide in Youth with Type 2 Diabetes: A Pivotal Phase III Randomized Study

WILLIAM V. TAMBORLANE, RAAFAT BISHAI, DAVID GELLER, NAIM SHEHADEH, DALIA AL-ABDULRAZZAQ, ÉVA KÁROLY, ORLANDO DOEHRING, DEBRA CARTER, JOHN MONYAK, C. DAVID SJÖSTRÖM

Diabetes 2021;70(Supplement_1):91-LB

https://doi.org/10.2337/db21-91-LB

Published: 01 June 2021

View article titled, 91-LB: Once-Weekly Exenatide in Youth with Type 2 Diabetes: A Pivotal Phase III Randomized Study

Meeting Abstracts

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

NICKLAS J. JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, CAMILLA SCHLÜNTZ, EMIL LIST LARSEN, HENRIK E. POULSEN, JENS P. GØTZE, HOLGER MØLLER, TINA VILSBØLL, HENRIK U. ANDERSEN, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):1094-P

https://doi.org/10.2337/db20-1094-P

Published: 01 June 2020

View article titled, 1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

Meeting Abstracts

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

MARIAM ALATRACH, CHRISTINA AGYIN, IV, JOHN M. ADAMS, II, OLGA LAVRYNENKO, NITCHAKARN LAICHUTHAI, EUGENIO CERSOSIMO, CURTIS L. TRIPLITT, AMALIA GASTALDELLI, MUHAMMAD ABDUL-GHANI, RALPH A. DEFRONZO

Diabetes 2020;69(Supplement_1):352-OR

https://doi.org/10.2337/db20-352-OR

Published: 01 June 2020

View article titled, 352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

Meeting Abstracts

1095-P: Exendin 4 Decreases Tumor Volume through Attenuation of psma-Induced Activation of NfκB Pathway in HPV-Induced Diabetes/Cancer Model

DANDAN MAO, JULIANA C. CHAN

Diabetes 2020;69(Supplement_1):1095-P

https://doi.org/10.2337/db20-1095-P

Published: 01 June 2020

View article titled, 1095-P: Exendin 4 Decreases Tumor Volume through Attenuation of psma-Induced Activation of NfκB Pathway in HPV-Induced Diabetes/Cancer Model

Meeting Abstracts

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

MARIAM ALATRACH, CHRISTINA AGYIN, IV, NITCHAKARN LAICHUTHAI, OLGA LAVRYNENKO, JOHN M. ADAMS, II, MUHAMMAD ABDUL-GHANI, CURTIS L. TRIPLITT, RALPH A. DEFRONZO, EUGENIO CERSOSIMO

Diabetes 2020;69(Supplement_1):1136-P

https://doi.org/10.2337/db20-1136-P

Published: 01 June 2020

View article titled, 1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

Meeting Abstracts

966-P: Effect of Baseline ß-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

CHAOFAN WANG, WEN XU, HONGRONG DENG, BEISI LIN, JING LV, LONGYI ZENG, BIN YAO, JIANPING WENG

Diabetes 2020;69(Supplement_1):966-P

https://doi.org/10.2337/db20-966-P

Published: 01 June 2020

View article titled, 966-P: Effect of Baseline ß-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

Meeting Abstracts

937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia

TSUNG-HUI WU, HARN-SHEN CHEN

Diabetes 2020;69(Supplement_1):937-P

https://doi.org/10.2337/db20-937-P

Published: 01 June 2020

View article titled, 937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia

Meeting Abstracts

928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data

REEMA MODY, MARIA YU, BAL K. NEPAL, MANIGE KONIG, MICHAEL GRABNER

Diabetes 2020;69(Supplement_1):928-P

https://doi.org/10.2337/db20-928-P

Published: 01 June 2020

View article titled, 928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data

Meeting Abstracts

958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis

LINDSAY E. CLEGG, ANNEMARIE VAN DER AART, ROBERT C. PENLAND, DAVID W. BOULTON, C. DAVID SJÖSTRÖM, ROBERT J. MENTZ, RURY R. HOLMAN, HIDDO L. HEERSPINK

Diabetes 2020;69(Supplement_1):958-P

https://doi.org/10.2337/db20-958-P

Published: 01 June 2020

View article titled, 958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis

Meeting Abstracts

26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study

XIANGYU WANG, QIAN ZHANG, MEIPING GUAN, SHUYUE SHENG, WEI MO, MENGCHEN ZOU, JIMIN LI, JIANLU BI, XIANYU TANG, JIALI HE, GUGEN XU, PING LI, HUIJIE ZHANG, YAOMING XUE

Diabetes 2020;69(Supplement_1):26-LB

https://doi.org/10.2337/db20-26-LB

Published: 01 June 2020

View article titled, 26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study

Meeting Abstracts

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

YANNA SU, WEN XU, BEISI LIN, ZIYU LIU, YALAN CHEN, ZHIWEI YE, LU GAN, BIN YAO

Diabetes 2020;69(Supplement_1):2106-P

https://doi.org/10.2337/db20-2106-P

Published: 01 June 2020

View article titled, 2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

Meeting Abstracts

520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway

MEIJUN WANG, RIYING LIANG, FEN XU, MENGYIN CAI

Diabetes 2020;69(Supplement_1):520-P

https://doi.org/10.2337/db20-520-P

Published: 01 June 2020

View article titled, 520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway

NARROW

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

233-OR: The Beta-Cell Specific Deletion of Complement 1q-Like-3 Secreted Protein Improves Beta-Cell Function and Glucose Homeostasis

14-OR: Harmine and Exenatide Combination Increases Human ß-Cell Survival

895-P: External Validation of the BRAVO Diabetes Model Using Data from the EXSCEL Study

10-OR: Combination Therapy with Anti-CD3 Antibody and Harmine plus Exendin-4 Enhances Remission from Recent-Onset Type 1 Diabetes.

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

229-LB: Quantification of GLP-1R Internalization and Recycling in Live ß Cells

641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide

91-LB: Once-Weekly Exenatide in Youth with Type 2 Diabetes: A Pivotal Phase III Randomized Study

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

1095-P: Exendin 4 Decreases Tumor Volume through Attenuation of psma-Induced Activation of NfκB Pathway in HPV-Induced Diabetes/Cancer Model

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

966-P: Effect of Baseline ß-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia

928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data

958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis

26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only